Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Long-Term Investments (2016 - 2021)

Lifecore Biomedical, Inc. \De\ has reported Long-Term Investments over the past 11 years, most recently at $44.8 million for Q2 2021.

  • For Q2 2021, Long-Term Investments fell 21.32% year-over-year to $44.8 million; the TTM value through May 2021 reached $44.8 million, down 21.32%, while the annual FY2021 figure was $44.8 million, 21.32% down from the prior year.
  • Long-Term Investments for Q2 2021 was $44.8 million at Lifecore Biomedical, Inc. \De\, down from $45.1 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $68.1 million in Q4 2018 and troughed at $44.8 million in Q2 2021.
  • A 5-year average of $60.3 million and a median of $62.4 million in 2017 define the central range for Long-Term Investments.
  • Biggest five-year swings in Long-Term Investments: grew 4.94% in 2017 and later fell 26.43% in 2020.
  • Year by year, Long-Term Investments stood at $65.8 million in 2017, then rose by 3.5% to $68.1 million in 2018, then decreased by 9.99% to $61.3 million in 2019, then fell by 26.43% to $45.1 million in 2020, then decreased by 0.73% to $44.8 million in 2021.
  • Business Quant data shows Long-Term Investments for LFCR at $44.8 million in Q2 2021, $45.1 million in Q1 2021, and $45.1 million in Q4 2020.